EP0639201A1 - 14,16beta-ETHANO-15beta,16' -CYCLO-14beta-ESTRA-1,3,5(10)-TRIENES - Google Patents

14,16beta-ETHANO-15beta,16' -CYCLO-14beta-ESTRA-1,3,5(10)-TRIENES

Info

Publication number
EP0639201A1
EP0639201A1 EP92902943A EP92902943A EP0639201A1 EP 0639201 A1 EP0639201 A1 EP 0639201A1 EP 92902943 A EP92902943 A EP 92902943A EP 92902943 A EP92902943 A EP 92902943A EP 0639201 A1 EP0639201 A1 EP 0639201A1
Authority
EP
European Patent Office
Prior art keywords
estra
ethano
cyclo
general formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92902943A
Other languages
German (de)
English (en)
Other versions
EP0639201A4 (fr
Inventor
James R. Bull
Walter Elger
Krzysztof Chwalisz
Karl-Heinrich Fritzemeier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of EP0639201A4 publication Critical patent/EP0639201A4/fr
Publication of EP0639201A1 publication Critical patent/EP0639201A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused

Definitions

  • the present invention relates to 14,16 ⁇ -ethano-15 ⁇ , 16 1 -cyclo-14 ⁇ -estra-1,3,5 (10) -trienes of the general formula I.
  • R 1 is a hydrogen atom, a C 1 to C 9 alkyl or C 1 to C 9 acyl radical,
  • R 2 is a hydrogen atom, a C 1 to C 9 alkyl, a C 2 to C 9 alkenyl or alkynyl radical and
  • R 3 is a hydroxy group or a C 1 to C 9 acyloxy radical
  • R 2 can be in the 17 ⁇ - as well as in the 17 ⁇ -position and accordingly R 3 in the 17 ⁇ - or 17 ⁇ -position.
  • radicals of organic carboxylic acids with 1-12 carbon atoms are suitable. They are derived from aliphatic, cycloaliphatic, aliphatic-cycloaliphatic, cycloaliphatic-aliphatic and aromatic monocarboxylic acids with 1 to 12 carbon atoms. The number of carbon atoms in the ring varies from 3 to 7.
  • the acyl groups of the vinegar, propion, butter, isobutter, pivaline, capron, acrylic, croton are preferred for the radicals R 1 , R 2 and R 3 -, heptyl, caprylic, pelargonium, decane, undecane,
  • acyl radicals R 1 , R 2 and the acyloxy radical R 3 should be derived from those carboxylic acids which have 2 to 8 carbon atoms.
  • the acyl groups R 1 , R 2 and R 3 can also contain up to 6 dicarboxylic acids
  • R 1 is an alkyl radical, the methyl radical is primarily considered; also that
  • Ethyl, propyl and isopropyl are of particular importance.
  • the cyclopentyl radical for R 1 is preferred as the cycloalkyl radical.
  • the compounds of the general formula I according to the invention have a strong affinity for the estrogen receptor and they also have high estrogenic activity after oral administration.
  • the compounds with high estrogenic activity are, for example, the natural estrogens estradiol and estriol (E. Schröder, C. Rufer and R. Schmiechen, Pharmaceutical Chemistry, 1982, Georg Thieme Verlag, Stuttgart-New York, p. 568 ff). However, they are not metabolically stable and are broken down after oral administration by oxidation of the 17-hydroxy group to the corresponding, ineffective estrone derivative.
  • the oxidation of the 17-hydroxy group can be prevented by introducing, for example, an ethynyl group on the 17 C atom (ethinyl estradiol, loc. Cit., P. 574) and the corresponding derivatives consequently have high estrogenic activity after oral administration.
  • an ethynyl group on the 17 C atom ethinyl estradiol, loc. Cit., P. 574
  • the corresponding derivatives consequently have high estrogenic activity after oral administration.
  • the estrogenic activity of the compounds according to the invention is demonstrated by the results of the estrogen receptor binding test.
  • tissue from rat uteri is prepared and radioactively labeled H-estradiol is used as the reference substance.
  • the compounds according to the invention (16 1 S) -14,16 ⁇ -ethano-15 ⁇ , 16 1 -cyclo-14 ⁇ -estra-1,3,5 (10) -triene3,17 ⁇ -diol (A) and (16 1 S) - 14,16 ⁇ -ethano-15 ⁇ , 16 1 -cyclo-14 ⁇ -estra-1,3,5 (10) -triene-3,17 ⁇ -diol (B) therefore have the following competition factors:
  • the invention thus also relates to the use of the compounds of the general formula I for the production of medicaments.
  • the compounds of the invention can be formulated and used in the same manner as ethinyl estradiol, which is the most widely used estrogen. They are processed with the additives, carrier substances and / or taste correctives customary in galenical pharmacy according to methods known per se to the usual pharmaceutical forms. Tablets, coated tablets, capsules, pills, suspensions or solutions are particularly suitable for oral administration.
  • oily solutions such as, for example, sesame oil or castor solutions, are suitable, which may also contain a diluent, such as, for example, benzyl benzoate or benzyl alcohol.
  • the active substance concentration in the pharmaceutical compositions depends on the form of application and the field of application.
  • capsules or tablets for the treatment of estrogen deficiency symptoms can contain 0.001 to 0.05 mg of active ingredient, oily solutions for intramuscular injection per 1 ml of about 0.01 to 0.1 mg of active ingredient and vaginal ointments about 0.1 to 10 mg per 100 ml of ointment contain.
  • the estrogens according to the invention can be used in combination with 6-stage be turned.
  • Tablets or coated tablets for daily intake of a tablet or coated tablet should preferably contain 0.003 to 0.05 mg of the estrogen according to the invention and 0.05 to 0.5 mg of a progestogen.
  • the compounds according to the invention can be used for symptoms of estrogen deficiency in women, such as, for example, amenorrhea, dysmenorrhea, sterility, endometritis, colpitis and climacteric complaints and for the prevention of osteoporosis.
  • the compounds can be used as an estrogenic component in hormonal contraceptives (single-phase and multi-phase and multi-stage preparations). In combination with other active substances, they are also suitable for use in hormone-bearing intrauterine devices, implantable active substance carriers and in transdermal application systems.
  • R 1 is a hydrogen atom, a C 1 to C 9 alkyl or C 1 to C 9 acyl radical,
  • R 2 is a hydrogen atom, a C 1 to C 9 alkyl, a C 2 to C 9 alkenyl or alkynyl radical and
  • R 3 is a hydroxy group or a C 1 to C 9 acyloxy radical
  • the 3-alkyl ethers of the general formula Ia are cleaved with diisobutylaluminium hydride in an inert solvent, for example toluene, at elevated temperature (in general under reflux boiling).
  • the alkyl group in the 3-alkyl ethers of the general formula II is split off under the same conditions.
  • a Lewis acid such as trimethylsilyl iodide in a polar solvent such as acetonitrile can also be used for ether cleavage.
  • the preparation of the starting compound of the general formula II is based on the known dienol acetate 1, which is reacted with chloroacrylonitrile in a Diels-Alder cycloaddition.
  • the reaction is preferably carried out under elevated pressure (2-20 bar) in an inert organic solvent such as benzene, toluene, dichloromethane at temperatures between 50-120 ° C carried out.
  • Aqueous 2M potassium hydroxide solution (1.1 ml; 2.2 mmol) is added with stirring to a solution of the cycloadduct (2) (360 mg; 0.87 mmol) in tetrahydrofuran (7.2 ml) and dimethyl sulfoxide (7.2 ml) under nitrogen 0 ° C given. After 3 hours, saturated aqueous ammonium chloride solution is added and the mixture is extracted with chloroform. The extract is washed with brine and water, dried (MgSO 4 ) and concentrated under reduced pressure.
  • a mixture of the carbonitrile (4) (540 mg; 1.6 mmol), ethylene glycol (2.0 ml) and para-toluenesulfonic acid (50 mg; 0.29 mmol) in toluene (54 ml) is slowly distilled in a Dean and Stark apparatus. After 7.5 hours, after the volume has decreased to approx. 30 ml, the mixture is refluxed for a further 17 hours while returning the condensate via molecular sieve (4A). Aqueous sodium hydrogen carbonate solution is added and the mixture is extracted with toluene. The extract is washed with water and sodium hydrogen carbonate solution, dried (MgSO 4 ) and evaporated under reduced pressure. The crystalline residue (632 mg) is recrystallized from chloroform / methanol to give the ketal (6) (565 mg; 92%).
  • a solution of the ketal (6) (400 mg; 1.06 mmol) in anhydrous toluene (80 ml) is treated at -78 ° C. under nitrogen with diisobutyl aluminum hydride (20% in hexane, 3.6 ml). After 160 minutes, aqueous ammonium chloride solution is added. The aqueous phase is acidified with dilute sulfuric acid and extracted with ethyl acetate, washed with aqueous sodium hydrogen carbonate solution and water, dried (MgSO 4 ) and evaporated to dryness under reduced pressure.
  • Diisobutylaluminum hydride (20% solution in hexane; 3.9 ml) is added with stirring to a solution of (10) (150 mg; 0.47 mmol) in toluene (27 ml) under nitrogen, the mixture is heated under reflux for 23.5 hours , cooled to room temperature and the reaction was terminated by adding aqueous ammonium chloride solution. Then ethyl acetate and then water are added. The mixture is acidified with hydrochloric acid and extracted with ethyl acetate.
  • Example 5c Analogously to Example 5c), 100 mg of the compound shown under a) are reacted in 1 ml of tetrahydrofuran with 154 mg of tetrabutytemmoinium fluoride trihydrate. The crude product is recrystallized from diisopropyl ether. 61 mg (20) are obtained as white crystals.
  • Example 5b Analogously to Example 5b), 100 mg of the compound shown under a) are reacted with 0.05 ml of triethylamine, 0.04 ml of acetic anhydride and a spatula tip of 4-dimethylaminopyridine in 2 ml of methylene chloride. 90 mg of 22 are obtained. which is used as a raw product in the next stage.
  • c) (16 1 S) -17 ⁇ - (acetyloxy) -14,16 ⁇ -ethano-15 ⁇ , 16 1 -cyclo-14 ⁇ -estra-1,3,5 (10) -trien-3-ol (23)
  • Example 5c Analogously to Example 5c), 90 mg of the compound shown under b) and 160 mg of tetrabutylammonium fluoride trihydrate are reacted in 1 ml of tetrahydrofuran. The crude product is recrystallized from diisopropyl ether. 50 mg of 23) are obtained as white crystals.
  • Example 6a Analogously to Example 6a, 100 mg of the compound shown in Example 7a) and 0.07 ml of benzoyl chloride are reacted in 0.6 ml of absolute pyridine. After chromatography, 95 mg (24) are obtained as a white foam.
  • Tetrabutylammonium fluoride trihydrate implemented in 1.5 ml of absolute tetrahydrofuran

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des 14,16beta-éthano-15beta,161 -cyclo-14beta-estra-1,3,5(10)-triènes répondant à la formule générale (I) dans laquelle R1 représente un atome d'hydrogène, un reste alkyle C1 à C9 ou un reste acyle C1 à C9; R2 représente un atome d'hydrogène, un reste alkyle C1 à C9, un reste alcényle ou alkynyle C2 à C9; et R3 représente un groupe hydroxy ou un reste acyloxy C1 à C9. L'invention concerne également un procédé de production de ces composés. Ces nouveaux composés présentent (administrés par voie orale) une grande efficacité et ils conviennent à la production de médicaments.
EP92902943A 1991-01-24 1992-01-24 14,16beta-ETHANO-15beta,16' -CYCLO-14beta-ESTRA-1,3,5(10)-TRIENES Withdrawn EP0639201A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4102244 1991-01-24
DE4102244A DE4102244A1 (de) 1991-01-24 1991-01-24 14,16ss-ethano-15ss, 16(pfeil hoch)1(pfeil hoch)-cyclo-14ss-estra-1,3,5(10)-triene
PCT/EP1992/000160 WO1992012990A1 (fr) 1991-01-24 1992-01-24 14,16β-ETHANO-15β,161 -CYCLO-14β-ESTRA-1,3,5(10)-TRIENES

Publications (2)

Publication Number Publication Date
EP0639201A4 EP0639201A4 (fr) 1993-09-17
EP0639201A1 true EP0639201A1 (fr) 1995-02-22

Family

ID=6423722

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92902943A Withdrawn EP0639201A1 (fr) 1991-01-24 1992-01-24 14,16beta-ETHANO-15beta,16' -CYCLO-14beta-ESTRA-1,3,5(10)-TRIENES

Country Status (5)

Country Link
US (1) US5418227A (fr)
EP (1) EP0639201A1 (fr)
JP (1) JPH06504780A (fr)
DE (1) DE4102244A1 (fr)
WO (1) WO1992012990A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD145919B1 (de) * 1978-06-28 1982-06-30 Kurt Ponsold Verfahren zur herstellung von 14,1 -methylenderivaten der oestranreihe
US4220775A (en) * 1979-03-15 1980-09-02 Merck & Co., Inc. Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
DE3130644A1 (de) * 1981-07-29 1983-02-17 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue androstan-derivate, verfahren zu ihrer herstellung und pharmazeutische praeparate, die diese verbindungen enthalten
DE3326013A1 (de) * 1983-07-15 1985-01-24 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-methylen-17(alpha)-pregna-4,6-dien-21-carbonsaeuresalze, diese enthaltende pharmazeutische praeparate sowie verfahren zu deren herstellung
DE3838779A1 (de) * 1988-11-11 1990-05-17 Schering Ag 14(alpha),17(alpha)-ethano-estratriene

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9212990A1 *

Also Published As

Publication number Publication date
DE4102244A1 (de) 1992-07-30
JPH06504780A (ja) 1994-06-02
EP0639201A4 (fr) 1993-09-17
US5418227A (en) 1995-05-23
WO1992012990A1 (fr) 1992-08-06

Similar Documents

Publication Publication Date Title
EP0970103B1 (fr) Steroides a activite antigestagene a chaine 17alpha-alkyle fluoree
DE69603425T2 (de) 11-Substituierte Phenyl-estra-4,9-dien Derivate
DE60025958T2 (de) 14,15-beta-methylen substituierte androgene
WO1990005139A1 (fr) 14α,17α-ETHANO-ESTRATRIENES
EP0318490B1 (fr) 14,17-g(b)-ETHANO-14-g(b)-ESTRATRIENES, PROCEDE POUR LEUR FABRICATION ET PREPARATIONS PHARAMCEUTIQUES LES CONTENANT
EP0642529B1 (fr) 14,17-ethanoestratrienes 11beta-substitues, procede de production de ces composes, et leur utilisation dans la production de medicaments
DE60020260T2 (de) Nicht-aromatische estrogenische steroide mit einem 11-hydrocarbyl substituent
DE69415812T2 (de) 15,15-dialkylsubstituierte östradiolderivate
EP0430386B1 (fr) 14Alpha, 17alpha portés-16-hydroxyestratriènes
EP0639201A1 (fr) 14,16beta-ETHANO-15beta,16' -CYCLO-14beta-ESTRA-1,3,5(10)-TRIENES
DE2417846A1 (de) In 7-stellung substituierte steroide der oestranreihe
EP0799238A2 (fr) Derives de 19-nor-progesterone a pontage 14alpha,17alpha-c2
EP0513947B1 (fr) 14Alpha, 16alpha-ethano- et 14alpha, 16alpha-etheno-estratriènes
EP0511727B1 (fr) 14-alpha,17alpha-(propano- et 17,2-propeno)-estratriènes
DE4018828C2 (de) Verfahren zur Herstellung C7-alpha-substituierter 8alpha- und 8ß-Estra-1,3,5(10)-triene und C8-alpha-substituierter Estra-1,3,5(10)-triene sowie neue Zwischenprodukte für dieses Verfahren
DE3144049A1 (de) 16(beta)-methyl-8(alpha)-oestradiole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
EP0034114A1 (fr) 3-Desoxy-delta 15-stéroides, procédé pour leur préparation et compositions pharmaceutiques les contenant
DE19934088A1 (de) Neue C-19-halogensubstituierte Steroide der Androst-9(11)-en-Reihe, Verfahren zu ihrer Herstellung sowie ihre Verwendung
DE3939894A1 (de) 14(alpha),17(alpha)-ethano-16(alpha)-hydroxy-estratriene
WO1993025569A1 (fr) ×stradiols utiles comme promedicaments
DE2101813A1 (de) Steroidverbindungen und Verfahren zu ihrer Herstellung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930524

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960801